These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23463086)

  • 1. Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases.
    van den Broek MA; Vreuls CP; Winstanley A; Jansen RL; van Bijnen AA; Dello SA; Bemelmans MH; Dejong CH; Driessen A; Olde Damink SW
    Ann Surg Oncol; 2013 May; 20(5):1462-9. PubMed ID: 23463086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy.
    Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Hanaoka J; Kanamoto M; Iwahashi S; Saito Y; Yamada S; Asanoma M; Takasu C; Bando Y
    Anticancer Res; 2014 Apr; 34(4):1953-8. PubMed ID: 24692731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.
    Soubrane O; Brouquet A; Zalinski S; Terris B; Brézault C; Mallet V; Goldwasser F; Scatton O
    Ann Surg; 2010 Mar; 251(3):454-60. PubMed ID: 20160638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis.
    Stevenson HL; Prats MM; Sasatomi E
    BMC Cancer; 2017 Jan; 17(1):35. PubMed ID: 28061766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases.
    Vreuls CP; Van Den Broek MA; Winstanley A; Koek GH; Wisse E; Dejong CH; Olde Damink SW; Bosman FT; Driessen A
    Histopathology; 2012 Aug; 61(2):314-8. PubMed ID: 22571348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases.
    Morris-Stiff G; White AD; Gomez D; Cameron IC; Farid S; Toogood GJ; Lodge JP; Prasad KR
    Eur J Surg Oncol; 2014 Aug; 40(8):1016-20. PubMed ID: 24370284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy.
    Tamandl D; Klinger M; Eipeldauer S; Herberger B; Kaczirek K; Gruenberger B; Gruenberger T
    Ann Surg Oncol; 2011 Feb; 18(2):421-30. PubMed ID: 20844968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver injury due to chemotherapy-induced sinusoidal obstruction syndrome is associated with sinusoidal capillarization.
    Narita M; Oussoultzoglou E; Chenard MP; Fuchshuber P; Rather M; Rosso E; Addeo P; Jaeck D; Bachellier P
    Ann Surg Oncol; 2012 Jul; 19(7):2230-7. PubMed ID: 22402811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
    Imai K; Emi Y; Iyama KI; Beppu T; Ogata Y; Kakeji Y; Samura H; Oki E; Akagi Y; Maehara Y; Baba H;
    Eur J Surg Oncol; 2014 May; 40(5):559-566. PubMed ID: 24388740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Influence of pre-surgical chemotherapy on liver parenchyma and post-surgical outcome of patients subjected to hepatectomy due to colorectal carcinoma metastases].
    Gómez-Ramírez J; Martín-Pérez E; Amat CG; Sanz IG; Bermejo E; Rodríguez A; Larrañaga E
    Cir Esp; 2010 Dec; 88(6):404-12. PubMed ID: 20971458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection.
    Duwe G; Knitter S; Pesthy S; Beierle AS; Bahra M; Schmelzle M; Schmuck RB; Lohneis P; Raschzok N; Öllinger R; Sinn M; Struecker B; Sauer IM; Pratschke J; Andreou A
    Eur J Surg Oncol; 2017 Sep; 43(9):1668-1681. PubMed ID: 28599872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases.
    Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T
    Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival.
    Viganò L; Capussotti L; De Rosa G; De Saussure WO; Mentha G; Rubbia-Brandt L
    Ann Surg; 2013 Nov; 258(5):731-40; discussion 741-2. PubMed ID: 24045448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
    Aloia T; Sebagh M; Plasse M; Karam V; Lévi F; Giacchetti S; Azoulay D; Bismuth H; Castaing D; Adam R
    J Clin Oncol; 2006 Nov; 24(31):4983-90. PubMed ID: 17075116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic complications following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases.
    Morris-Stiff G; Tan YM; Vauthey JN
    Eur J Surg Oncol; 2008 Jun; 34(6):609-14. PubMed ID: 17764887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyaluronic acid as a marker of sinusoidal obstruction syndrome after oxaliplatin-based chemotherapy for colorectal liver metastases: don't forget the tumor.
    Rahbari NN; Weitz J
    Ann Surg Oncol; 2013 May; 20(5):1405-7. PubMed ID: 23463087
    [No Abstract]   [Full Text] [Related]  

  • 17. Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model.
    Robinson SM; Mann J; Vasilaki A; Mathers J; Burt AD; Oakley F; White SA; Mann DA
    J Hepatol; 2013 Aug; 59(2):318-26. PubMed ID: 23624001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases.
    Khan AZ; Morris-Stiff G; Makuuchi M
    J Hepatobiliary Pancreat Surg; 2009; 16(2):137-44. PubMed ID: 19093069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic Parenchymal Heterogeneity as a Marker for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome: Correlation With Treatment Response of Colorectal Cancer Liver Metastases.
    Han NY; Park BJ; Yang KS; Kim MJ; Sung DJ; Sim KC; Cho SB
    AJR Am J Roentgenol; 2017 Nov; 209(5):1039-1045. PubMed ID: 28813196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sinusoidal dilation increases the risk of complications in hepatectomy for CRCLM - Protective effect of bevacizumab and diabetes mellitus, serum gamma-glutamyltranspeptidase as predictive factor.
    Martins J; Alexandrino H; Oliveira R; Cipriano MA; Falcão D; Ferreira L; Martins R; Serôdio M; Martins M; Tralhão JG; Prado e Castro L; Castro E Sousa F
    Eur J Surg Oncol; 2016 May; 42(5):713-21. PubMed ID: 26972374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.